Pipettes in a row

Research Pipeline

With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our five areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, are being developed in collaboration with Sangamo Therapeutics,  are being developed in collaboration with Roche, are being developed in collaboration with SOBI, ✿ are being developed in collaboration with Revolution Medicines, , are being developed in collaboration with BioNtech, are being developed in collaboration with Immunext, are being developed in collaboration with Denali, ➤ are being developed in collaboration with Lead Pharma and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a ✜ denote a Phase 1/2 trial. Items shown with a denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc. Items shown with ♠ denote opt in rights product for which rights have not been exercised yet. Items shown with ❒ denote identification of out-licensing partner ongoing.

Product Candidate Technology Phase I Phase II Phase III Current Phase

Rare Diseases

Eliglustat
Gaucher disease Type 1, ERT switch Pediatric
protein-based therapy Eliglustat Gaucher disease Type 1 Pediatric, ERT switch - Phase I - 100% of progress Eliglustat Gaucher disease Type 1 Pediatric , ERT switch - Phase II - 100% of progress Eliglustat Gaucher disease Type 1 Pediatric , ERT switch - Phase III - 25% of progress PHASE III
Avalglucosidase alfa
Pompe disease
protein-based therapy Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase I - 100% of progress Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase II - 100% of progress Avalglucosidase alfa Pompe disease, 2nd generation enzyme - Phase III - 25% of progress PHASE III
Venglustat
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
small molecule Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase I - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase II - 100% of progress Venglustat Autosomal Dominant Polycystic Kidney Disease - Phase III - 25% of progress PHASE III
Olipudase Alfa†
Acid Sphingomyelinase Deficiency (ASMD)
protein-based therapy Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase I - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase II - 100% of progress Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD) - Phase III - 0% of progress PHASE II
Venglustat
Fabry disease
small molecule venglustat Fabry disease - Phase I - 100% of progress venglustat Fabry disease - Phase II - 100% of progress venglustat Fabry disease - Phase III - 0% of progress PHASE II
Venglustat
Gaucher disease Type 3
small molecule venglustat Gaucher Type 3 - Phase I - 100% of progress venglustat Gaucher Type 3 - Phase II - 50% of progress venglustat Gaucher Type 3 - Phase III - 0% of progress PHASE II
SAR339375
Alport Syndrome
miRNA-21  SAR339375 Alport Syndrome - Phase II - 100% of progress SAR339375 Alport Syndrome - Phase II - 25% of progress SAR339375 Alport Syndrome - Phase III - 0% of progress PHASE II

Rare Blood Disorders

Fitusiran
Hemophilia A & B
RNAi Fitusiran* Hemophilia A & B - Phase I - 100% of progress Fitusiran* Hemophilia A & B - Phase II - 100% of progress Fitusiran* Hemophilia A & B - Phase III - 50% of progress PHASE III
Fitusiran
Hemophilia A & B - pediatric
RNAi Fitusiran* Hemophilia A & B-pediatric - Phase I - 100% of progress Fitusiran* Hemophilia A & B-pediatric - Phase II - 100% of progress Fitusiran* Hemophilia A & B-pediatric - Phase III - 50% of progress PHASE III
Sutimlimab
Cold Agglutinin Disease
mAb to C1s Sutimlimab Cold Agglutinin Disease - Phase I - 100% of progress Sutimlimab Cold Agglutinin Disease - Phase II - 100% of progress Sutimlimab Cold Agglutinin Disease - Phase III - 50% of progress PHASE III
BIVV001✜
Hemophilia A
Extended Half Life Factor BIVV001 Hemophilia A - Phase I - 100% of progress BIVV001 Hemophilia A - Phase II - 50% of progress BIVV001 Hemophilia A - Phase III - 0% of progress PHASE I/II
ST400
Beta Thalassemia
ZFN Gene Editing ST400 Beta Thalassemia - Phase I - 100% of progress ST400 Beta Thalassemia - Phase II - 0% of progress ST400 Beta Thalassemia - Phase III - 0% of progress PHASE I/II
BIVV003❅
Sickle Cell Disease
ZFN Gene Editing BIVV003 Sickle Cell Disease - Phase I - 100% of progress BIVV003 Sickle Cell Disease - Phase II - 0% of progress BIVV003 Sickle Cell Disease  - Phase III - 0% of progress PHASE I/II
Sutimlimab
Immune Thrombocytopenic Purpura
mAb to C1s Sutimlimab Immune Thrombocytopenic Purpura - Phase I - 25% of progress Sutimlimab Immune Thrombocytopenic Purpura - Phase II - 0% of progress Sutimlimab Immune Thrombocytopenic Purpura - Phase III - 0% of progress PHASE I
BIVV020
Cold Agglutinin Disease
mAb to C1s BIVV020 Cold Agglutinin Disease - Phase I - 25% of progress BIVV020 Cold Agglutinin Disease - Phase II - 0% of progress BIVV020 Cold Agglutinin Disease - Phase III - 0% of progress PHASE I

Multiple Sclerosis/Neurology

Teriflunomide
Relapsing Multiple Sclerosis - Pediatric
small molecule Teriflunomide Relapsing Multiple Sclerosis - Pediatric - Phase I - 100% of progress Teriflunomide Relapsing Multiple Sclerosis - Phase II - 100% of progress Teriflunomide Relapsing Multiple Sclerosis - Phase III - 50% of progress PHASE III
Alemtuzumab
Relapsing Remitting Multiple Sclerosis - Pediatric
mAb Alemtuzumab Relapsing Remitting Multiple Sclerosis - Pediatric - Phase I - 100% of progress Alemtuzumab Relapsing Remitting Multiple Sclerosis - Phase II - 100% of progress Alemtuzumab Relapsing Remitting Multiple Sclerosis - Phase III - 50% of progress PHASE III
SAR422459
Stargardt Disease
gene therapy SAR422459 Stargardt Disease - Phase I - 100% of progress SAR422459 Stargardt Disease - Phase II - 50% of progress SAR422459 Stargardt Disease - Phase III - 0% of progress PHASE II
SAR442168♦
Multiple Sclerosis
BTK inhibitor SAR442168 Multiple Sclerosis- Phase I - 100% of progress SAR442168 Multiple Sclerosis - Phase II - 25% of progress SAR442168 Multiple Sclerosis - Phase III - 0% of progress PHASE II
Venglustat
Parkinson's disease with a GBA mutation
small molecule venglustat Parkinson's disease with a GBA mutation - Phase I - 100% of progress venglustat Parkinson's disease with a GBA mutation - Phase II - 25% of progress venglustat Parkinson's disease with a GBA mutation - Phase III - 0% of progress PHASE II
SAR443060
Amyotrophic Lateral Sclerosis
RIPK1 inhibitor SAR443060 Amyotrophic Lateral Sclerosis - Phase I - 100% of progress SAR443060 Amyotrophic Lateral Sclerosis - Phase II - 0% of progress SAR443060 Amyotrophic Lateral Sclerosis - Phase III - 0% of progress PHASE I
SAR443060
Multiple Sclerosis
RIPK1 inhibitor SAR443060 Multiple Sclerosis - Phase I - 100% of progress SAR443060 Multiple Sclerosis - Phase II - 0% of progress SAR443060 Solid tumors - Phase III - 0% of progress PHASE I
SAR441344⚜
Multiple Sclerosis
mAb SAR441344 Multiple Sclerosis - Phase I - 50% of progress SAR441344 Multiple Sclerosis - Phase II - 0% of progress SAR441344 Multiple Sclerosis - Phase III - 0% of progress PHASE I

Oncology

Isatuximab
3L Relapsing Refractory Multiple Myeloma (ICARIA)
mAb Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA) - Phase I - 100% of progress Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA) - Phase II - 100% of progress Isatuximab 3L Relapsing Refractory Multiple Myeloma (ICARIA)- Phase III - 100% of progress PHASE III
Isatuximab
2L Relapsing Refractory Multiple Myeloma (IKEMA)
mAb Isatuximab Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress Isatuximab Relapsing Refractory Multiple Myeloma - Phase II - 100% of progress Isatuximab Relapsing Refractory Multiple Myeloma - Phase III - 50% of progress PHASE III
Isatuximab
1L Newly Diagnosed Multiple Myeloma (IMROZ)
mAb Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase I - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase II - 100% of progress Isatuximab 1L Newly Diagnosed MM (IMROZ) - Phase III - 25% of progress PHASE III
Isatuximab
Newly Diagnosed Multiple Myeloma (GMMG)
mAb Isatuximab Newly Diagnosed MM - Phase I - 100% of progress Isatuximab Newly Diagnosed MM - Phase II - 100% of progress Isatuximab Newly Diagnosed MM - Phase III - 25% of progress PHASE III
Cemiplimab^▼
2L Cervical Cancer
mAb Cemiplimab^  2L Cervical Cancer - Phase I - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase II - 100% of progress Cemiplimab^  2L Cervical Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼
adjuvant in Cutaneous Squamous Cell Carcinoma (CSCC)
mAb Cemiplimab^  adjuvant in CSCC - Phase I - 100% of progress Cemiplimab^  adjuvant in CSCC - Phase II - 100% of progress Cemiplimab^  adjuvant in CSCC - Phase III - 25% of progress PHASE III
Cemiplimab^▼
1L Non-small Cell Lung Cancer
mAb Cemiplimab^ Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^ Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Cemiplimab^▼ + Chemotherapy
1L Non-small Cell Lung Cancer
mAb Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer - Phase I - 100% of progress Cemiplimab^▼ + Chemotherapy 1L Non-small Cell Lung Cancer - Phase II - 100% of progress Cemiplimab^▼ + Chemotherapy  1L Non-small Cell Lung Cancer - Phase III - 25% of progress PHASE III
Isatuximab + Cemiplimab^
Relapsing Refractory Multiple Myeloma
mAb  isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase I - 100% of progress isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase II - 50% of progress isatuximab + Cemiplimab^ Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress PHASE II 
Isatuximab + Cemiplimab^
Lymphoma
mAb  isatuximab + Cemiplimab^ Lymphoma - Phase I - 100% of progress isatuximab + Cemiplimab^ Lymphoma - Phase II - 50% of progress isatuximab + Cemiplimab^ Lymphoma - Phase III - 0% of progress PHASE II 
Isatuximab + atezolizumab♕
Metastatic Colorectal Cancer
mAb  isatuximab + atezolizumab^ mCRC- Phase I - 100% of progress isatuximab + atezolizumab^ mCRC - Phase II - 50% of progress isatuximab + atezolizumab^ mCRC - Phase III - 0% of progress PHASE II 
Isatuximab + atezolizumab♕
Solid Tumors
mAb  isatuximab + atezolizumab^ Solid Tumors - Phase I - 100% of progress isatuximab + atezolizumab^ Solid Tumors - Phase II - 50% of progress isatuximab + atezolizumab^ Solid Tumors - Phase III - 0% of progress PHASE II 
Isatuximab
1-2L Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) - Pediatrics
mAb Isatuximab 1-2L AML/ALL - Pediatrics - Phase I - 100% of progress  Isatuximab 1-2L AML/ALL - Pediatrics - Phase II - 50% of progress Isatuximab 1-2L AML/ALL - Pediatrics - Phase III - 0% of progress PHASE II
Cemiplimab^▼
2-L Basal Cell Carcinoma (BCC)
mAb Cemiplimab^ Advanced BCC - Phase I - 100% of progress Cemiplimab^ Advanced BCC - Phase II - 50% of progress Cemiplimab^ Advanced BCC - Phase III - 0% of progress PHASE II
SAR439459
Advanced Solid Tumors 
mAb SAR439459 Advanced Solid Tumors - Phase I - 50% of progress SAR439459 Advanced Solid Tumors - Phase II - 0% of progress SAR439459 Advanced Solid Tumors - Phase III - 0% of progress PHASE I
SAR408701
Non-Small Cell Lung Cancer
Anti-body drug conjugate SAR408701 Non-Small Cell Lung Cancer - Phase I - 50% of progress SAR408701 Non-Small Cell Lung Cancer - Phase II - 0% of progress SAR408701 Non-Small Cell Lung Cancer - Phase III - 0% of progress PHASE I
REGN5458^
Relapsing Refractory Multiple Myeloma
Bi-specific mAb REGN5458 Relapsing Refractory Multiple Myeloma - Phase I - 50% of progress REGN5458 Relapsing Refractory Multiple Myeloma - Phase II - 0% of progress REGN5458 Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress PHASE I
REGN4018^
Ovarian Cancer
Bi-specific mAb REGN4018 Ovarian Cancer - Phase I - 50% of progress REGN4018 Ovarian Cancer - Phase II - 0% of progress REGN4018 Ovarian Cancer - Phase III - 0% of progress PHASE I
SAR442720
Solid Tumors
Small Molecule SAR442720 Solid tumors - Phase I - 50% of progress SAR442720 Solid tumors - Phase II - 0% of progress SAR442720 Solid tumors - Phase III - 0% of progress PHASE I
SAR440234
Leukemia
Bi-specific mAb SAR440234 Leukemia - Phase I - 50% of progress SAR440234 Leukemia - Phase II - 0% of progress SAR440234 Leukemia - Phase III - 0% of progress PHASE I
SAR441000⚙
Solid Tumors
Cytokine encoding mRNA SAR441000 Melanoma - Phase I - 50% of progress SAR441000 Melanoma - Phase II - 0% of progress SAR441000 Melanoma - Phase III - 0% of progress PHASE I
SAR439859
Metastatic Breast Cancer
Small Molecule SAR439859 (SERD) Metastatic Breast Cancer- Phase I - 50% of progress SAR439859 (SERD) Metastatic Breast Cancer - Phase II - 0% of progress SAR439859 (SERD) Metastatic Breast Cancer - Phase III - 0% of progress PHASE I
SAR439459 + cemiplimab^ 
Advanced Solid Tumors
mAb SAR439459 + cemiplimab Advanced Solid Tumors- Phase I - 50% of progress SAR439459 + cemiplimab Advanced Solid Tumors - Phase II - 0% of progress SAR439459 + cemiplimab Advanced Solid Tumors - Phase III - 0% of progress PHASE I
SAR439859 + palbociclib
Metastatic Breast Cancer
Small Molecule SAR439859 + palbociclib Metastatic Breast Cancer - Phase I - 50% of progress SAR439859 + palbociclib Metastatic Breast Cancer  - Phase II - 0% of progress SAR439859 + palbociclib Metastatic Breast Cancer  - Phase III - 0% of progress PHASE I
cemiplimab +REGN4018^♠ 
Ovarian Cancer
mAb cemiplimab +REGN4018 Ovarian Cancer- Phase I - 50% of progress cemiplimab +REGN4018 Ovarian Cancer - Phase II - 0% of progress cemiplimab +REGN4018 Ovarian Cancer - Phase III - 0% of progress PHASE I
SAR442085
Multiple Myeloma
mAb SAR442085 Multiple Myeloma- Phase I - 25% of progress SAR442085 Multiple Myeloma - Phase II - 0% of progress SAR442085 Multiple Myeloma - Phase III - 0% of progress PHASE I
REGN5459♠ 
Relapsing Refractory Multiple Myeloma
Bi-specific mAb REGN5459 Relapsing Refractory Multiple Myeloma - Phase I - 25% of progress REGN5459 Relapsing Refractory Multiple Myeloma - Phase II - 0% of progress REGN5459 Relapsing Refractory Multiple Myeloma - Phase III - 0% of progress PHASE I
SAR442720 + cobimetinib
Relapsing Refractory Solid Tumors
Bi-specific mAb SAR442720 + cobimetinib Relapsing Refractory Solid Tumors - Phase I - 25% of progress SAR442720 + cobimetinib Relapsing Refractory Solid Tumors - Phase II - 0% of progress SAR442720 + cobimetinib Relapsing Refractory Solid Tumors - Phase III - 0% of progress PHASE I

Immunology

Dupilumab^
Atopic Dermatitis (6-11 years old)
mAb Dupixent Atopic Dermatitis (6-11 years old) - Phase I - 100% of progress Dupixent Atopic Dermatitis (6-11 years old) - Phase II - 100% of progress Dupixent Atopic Dermatitis (6-11 years old) - Phase III - 25% of progress PHASE III
Dupilumab^
Atopic Dermatitis (6 mo - 5 years old)
mAb Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase I - 100% of progress Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase II - 100% of progress Dupixent Polyarticular Juvenile Idiopathic Atopic Dermatitis (6 mo - 5 years old) - Phase III - 25% of progress PHASE III
Dupilumab^
Asthma (6-11 years old)
mAb Dupilumab^ Asthma - Phase I - 100% of progress Dupilumab^ Asthma - Phase II - 100% of progress Dupilumab^ Asthma - Phase III - 25% of progress PHASE III
Dupilumab^
Eosinophilic Esophagitis
mAb Dupilumab^ Eosinophilic esophagitis - Phase I - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase II - 100% of progress Dupilumab^ Eosinophilic esophagitis - Phase III - 25% of progress PHASE III
Sarilumab^
Giant Cell Arteritis
mAb Sarilumab^  Giant Cell Arteritis - Phase I - 100% of progress Sarilumab^  Giant Cell Arteritis - Phase II - 100% of progress Sarilumab^  Giant Cell Arteritis - Phase III - 25% of progress PHASE III
Sarilumab^
Polymyalgia Rheumatica
mAb Sarilumab^ Polymyalgia Rheumatica - Phase I - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase II - 100% of progress Sarilumab^ Polymyalgia Rheumatica - Phase III - 25% of progress PHASE III
Dupilumab^
COPD
mAb Dupilumab COPD - Phase I - 100% of progress Dupilumab COPD - Phase II - 100% of progress Dupilumab COPD - Phase III - 25% of progress PHASE III
Dupilumab^
Grass Pollen Allergy
mAb Dupilumab^ Grass Pollen Allergy - Phase I - 100% of progress Dupilumab^ Grass Pollen Allergy - Phase II - 50% of progress Dupilumab^ Grass Pollen Allergy- Phase III - 0% of progress PHASE II
Dupilumab^
Peanut Allergy - Pediatric
mAb Dupilumab^ +AR101- Phase I - 100% of progress Dupilumab^ +AR101- Phase II - 50% of progress Dupilumab^ +AR101- Phase III - 0% of progress PHASE II
SAR440340^
Asthma
mAb SAR440340 Asthma - Phase I - 100% of progress SAR440340 Asthma - Phase II - 25% of progress SAR440340 Asthma - Phase III - 0% of progress PHASE II
SAR440340^
COPD
mAb SAR440340 COPD - Phase I - 100% of progress SAR440340 COPD - Phase II - 25% of progress SAR440340 COPD - Phase III - 0% of progress PHASE II
Sarilumab^
Polyarticular Juvenile Idiopathic Arthritis
mAb Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase I - 100% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase II - 25% of progress Sarilumab Polyarticular Juvenile Idiopathic Arthritis - Phase III - 0% of progress PHASE II
Sarilumab^
Systemic Juvenile Arthritis
mAb Sarilumab Systemic Juvenile Arthritis - Phase I - 100% of progress Sarilumab Systemic Juvenile Arthritis - Phase II - 25% of progress Sarilumab Systemic Juvenile Arthritis - Phase III - 0% of progress PHASE II
SAR156597^
Systemic Scleroderma
mAb Systemic Scleroderma - Phase I - 100% of progress SSystemic Scleroderma - Phase II - 25% of progress Systemic Scleroderma - Phase III - 0% of progress PHASE II
SAR440340^
Atopic Dermatitis
mAb Systemic Scleroderma - Phase I - 100% of progress SSystemic Scleroderma - Phase II - 25% of progress Systemic Scleroderma - Phase III - 0% of progress PHASE II
SAR441169
Psoriasis
Small Molecule Systemic Scleroderma - Phase I - 100% of progress SSystemic Scleroderma - Phase II - 0% of progress Systemic Scleroderma - Phase III - 0% of progress PHASE I
SAR441236
HIV
mAb SAR441236 HIV - Phase I - 25% of progress SAR441236 HIV - Phase II - 0% of progress SAR441236 HIV - Phase III - 0% of progress PHASE I
SAR443122
Systemic Inflammatory disease
RIPK1 inhibitor SAR443122 Systemic Inflammatory disease - Phase I - 25% of progress SAR443122 Systemic Inflammatory disease - Phase II - 0% of progress SAR443122 Systemic Inflammatory disease - Phase III - 0% of progress PHASE I

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remyelination.

Scientist in lab

Avalglucosidase alfa clinical trial

Learn more about the ongoing phase 3 clinical trial for avalglucosidase alfa, an investigational enzyme replacement therapy being studied for the treatment of Pompe disease.
Scientist at microscope

Sanofi’s R&D portfolio

The full Sanofi research pipeline focuses on finding innovative solutions to a variety of major public health challenges.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.
OK